Trial · NCT01291641
Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease
NCT01291641, Phase 4, Completed, Seoul National University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease. Trials, record NCT01291641. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01291641
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease
- NCT number
- NCT01291641
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 342 participants, actual
- Lead sponsor
- Seoul National University Hospital
- Conditions
- Hyperlipidemias
- Interventions
- HMG-CoA Reductase Inhibitor, Probucol, Cilostazol
- First posted
- 2011-02-08
- Last updated
- 2019-09-20
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Difference of Carotid artery IMT (mean IMT) between screening and treatment completion(3 years after) or discontinuation | Baseline(screening), 3years | For primary endpoint of Carotid artery IMT, t-test will be conducted for the mean IMT and variation by treatment arm(Group A vs B, Group A vs C). The 2-sided significance level is 5%. Morever, Mantel - Haenszel method can be accepted considering stratification factor or Sub-analysis can be done by each stratum in case of categorical variables. |
| Secondary | Time from enrollment date to the onset of composite cerebrovascular events | enrollment date, onset date(during study period, 3years) | 1. Cardiovascular death 2. Myocardial infarction 3. Cerebral infarction 4. Unstable angina and cardiac failure, required hospitalization 5. Coronary revascularization, required hospitalization 6. PCI and coronary artery bypass grafting \[CABG\] Kaplan-Meier method will be conducted for the time from enrollment date to the onset of composite cerebrovascular and cardiovascular events by treatment arm(Group A vs B, Group A vs C). Overall survival curves and progression-free survival curves are estimated per treatment arm. |
| Secondary | Number of composite cerebrovascular and cardiovascular events(including intervention) | enrollment date, onset date(during study period, 3years) | 1. Cardiovascular death 2. Myocardial infarction 3. Cerebral infarction 4. Unstable angina and cardiac failure, required hospitalization 5. Coronary revascularization, required hospitalization 6. PCI and coronary artery bypass grafting \[CABG\] For the number of composite cerebrovascular and cardiovascular events (including intervention) t-test will be done by treatment arm(Group A vs B, Group A vs C). |
| Secondary | The change of Biomarkers(1) | enrollment date ,onset date(during study period, 3years) | Metabolic index: Lipid profile (TC, LDL-C, HDL-C, TG) |
| Secondary | The change of Biomarkers(2) | enrollment date ,onset date(during study period, 3years) | Inflammatory index: High sensitive C-reactive protein (hsCRP) |
| Secondary | The change of Biomarkers(3) | enrollment date ,onset date(during study period, 3years) | Oxidation index:oxidized LDL The change of biomarkers, t-test will be done by treatment arm(Group A vs B, Group A vs C). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers25
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01291641
GET https://conductscience.org/api/trials/v1/NCT01291641/papers?page=2